MBLI’s RIP-Chip technology is designed to provide insights into new cellular pathway components, potential therapeutic targets, and provide information regarding the effects of drugs on post-transcriptional processes. This patented technology can be used for a variety of applications and research such as drug screening, cancer, diabetes, and disease response.

• Biological approach to find functionally related genes of disease pathways.

• Analyze post-transcriptional regulated genes

• Establish novel components of cellular pathways

• Identify new drug mechanisms

• Saves TIME (Identification of RNAs in RNP complexes can be done in a few hours!)

• High Specificity!

• Consistent Results!

RIP Validated Antibody Offering:

The RIP-Certified Antibodies have been validated for use with the optimized RiboCluster Profiler™ RIP-Assay Kit. The ability to immunoprecipitate mRNAs and RBPs complexes was confirmed by quantitative and qualitative analysis on NanoDrop, Bioanalyzer and RT-PCR or microarray.